A5012065980- Meningioma and schwannoma management
- Histone Deacetylase Inhibitors Research
- Glioma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Pituitary Gland Disorders and Treatments
- Neurofibromatosis and Schwannoma Cases
- Protein Degradation and Inhibitors
- Sarcoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Animal Virus Infections Studies
- SARS-CoV-2 and COVID-19 Research
- Chromatin Remodeling and Cancer
- Testicular diseases and treatments
- Cancer Treatment and Pharmacology
- Oral and Maxillofacial Pathology
- Adrenal and Paraganglionic Tumors
- Viral Infections and Immunology Research
- Gestational Trophoblastic Disease Studies
- Viral gastroenteritis research and epidemiology
University of Utah
2024
University of Colorado Anschutz Medical Campus
2019-2022
University of Colorado Boulder
2020-2022
University of Colorado Denver
2019-2021
University of Colorado System
2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing sufficiently potent clinical development and retain activity despite remain elusive. We identified human mAb, designated VIR-7229, which targets the receptor-binding motif (RBM) with unprecedented cross-reactivity all sarbecovirus clades,...
Background: Meningiomas are the most common primary central nervous system tumors. 20–30% of these tumors considered high-grade and associated with poor prognosis high recurrence rates. Despite occurrence meningiomas, there no FDA-approved compounds for treatment Methods: In this study, we screened patient-cultured meningiomas an epigenetic compound library to identify targetable mechanisms potential Meningioma cell cultures were generated directly from surgically resected patient cultured...
The recurring spillover of pathogenic coronaviruses and demonstrated capacity sarbecoviruses, such SARS-CoV-2, to rapidly evolve in humans underscores the need better understand immune responses this virus family. For purpose, we characterized functional breadth potency antibodies targeting receptor binding domain (RBD) spike glycoprotein that exhibited cross-reactivity against SARS-CoV-2 variants, SARS-CoV-1 sarbecoviruses from diverse clades animal origins with potential. One neutralizing...
Abstract Meningiomas are a common central nervous system (CNS) tumor, accounting for one third of CNS neoplasms. To date, no FDA approved pharmacotherapy exists meningiomas. In an effort to identify potential treatments meningiomas we created culture that allows us grow and screen tumors across hundreds compounds within two weeks resection. We screened 32 meningiomas, six which were World Health Organization (WHO) grade II, against the National Cancer Institute’s (NCI) FDA-approved cancer...
Background: Meningiomas are the most common primary tumor in central nervous system. Aside from surgery, no consensus on benefit of adjuvant therapy exists for these tumors. One possible avenue to address need additional therapies meningiomas is high-throughput drug screening. Through our screening efforts, we identified platelet-derived growth factor receptor (PDGFR) inhibitors as potential treatments patients with meningiomas.
Background: Meningiomas are common central nervous system tumors with few treatment options aside from surgery. Approximately 20 to 35% of these diagnosed as a WHO grade 2 or 3, necessitating great need for additional therapies. To address this need, we previously reported our results on high-throughput screening 30 meningiomas against panel FDA approved drugs well epigenetic inhibitors. Both panels indicated several Histone Deacetylase (HDAC) inhibitors possible targets, the most...
Background: Chordoma and chondrosarcoma are rare tumors of the central nervous system. Once thought as related tumors, genetic molecular profiling has resulted in their independent classification. Chordomas have a 5-year survival rate 61%, while rates 29 to 90% depending on grade. Adjuvant therapy for chordomas CNS highly debated. The poor patient outcomes lack therapeutic options these patients require additional research identify novel therapies treat tumors. Some studies found high...
Objective: Meningiomas are common brain neoplasms that account for 33.8% of all primary tumors. Approximately 20 to 35% meningiomas considered higher grade by the World Health Organization which have poor clinical outcomes. Lower also been shown cause long-term neurological deficits and reduced overall survival. Despite high incidence these tumors, lack an FDA-approved compound treatment. To address a pharmacological agent available meningiomas, we maintain on-going high-throughput screening...
Objective: Meningiomas are common, comprising 33.8% of primary brain neoplasms. Historically, meningiomas were once considered a benign tumor; however, recent epidemiologic studies now categorize 20 to 35% as higher-grade, exhibiting malignant characteristics and poor prognosis. Additionally, lower-grade known cause long-term neurological deficits reduced overall survival. Given the prevalence outcomes for these tumors, pharmacotherapies need be identified their treatment. One potential...
Objective: Epigenetics are fundamental to meningioma biology and can determine treatment sensitivity clinical course more accurately than current histopathologic methods. Despite this importance, epigenetics have not been widely considered as targets for the development of novel treatments meningioma. Considering World Health Organization recognizes between 20 35% meningiomas higher grade, low grade still result in long term neurological deficit decreased overall survival, need find...
Abstract Background Epigenetics may predict treatment sensitivity and clinical course for patients with meningiomas more accurately than histopathology. Nonetheless, targeting epigenetic mechanisms is understudied pharmacotherapeutic development these tumors. The bio-molecular insights potential therapeutic of meningioma epigenetics led us to investigate inhibition in meningiomas. Methods We screened a 43-tumor cohort using 139-compound inhibitor library assess relevant subgroups inhibition....
Abstract BACKGROUND 28% of primary central nervous system tumors are glioma and glioblastoma. These responsible for 80% malignant brain neoplasms most tumor related deaths. Despite modern therapies, patients with grade II gliomas have an average survival 8-15 years, while III 3-5 glioblastoma 12-15 months. The lack a curative treatment this group supports additional research novel approaches to identify more effective therapies. METHODS In study, we developed high-throughput drug screen...
Abstract BACKGROUND Glioma and glioblastoma comprise 28% of all primary central nervous system tumors cause the majority brain tumor deaths. Despite substantial research into molecular pathogenesis genetic landscape glioma, no currently approved therapies are curative for any glioma or glioblastoma. Patients with have an average survival time 12-15 months, while patients grade III gliomas 3-5 years, II 8-15 years. The lack a treatment these necessitates additional novel therapies. METHODS In...
Abstract BACKGROUND Chordoma is a rare malignant tumor with poor surgical control and no existing pharmacotherapies. Therefore, these tumors require additional research into novel therapeutics for their treatment. METHODS In this study we created high-throughput drug screen culture system to evaluate the efficacy of FDA-approved compounds in 10 chordoma cell lines primary tumors. The were graciously donated by Foundation. Primary collected from our operating room. vivo validation using three...
Abstract BACKGROUND Chordoma is a rare malignant tumor with few treatment options. While surgical resection deemed the most effective treatment, 5-year overall survival rate 61% and recurrence free approximately 50%. To date, no FDA approved pharmacotherapies exist for of chordoma, adjuvant therapy remains highly debated. This necessitates need further research to provide clinicians more options treat this patient population. METHODS In study, we conducted high-throughput 139-compound...